Izotropic Corporation has announced promising scientific research results related to its IzoView Breast CT Imaging System. The findings highlight IzoView's potential to revolutionize breast cancer imaging by offering true 3D imaging without the need for breast compression, effectively bridging the gap between digital breast tomosynthesis (DBT) and magnetic resonance imaging $(MRI.AU)$. IzoView is designed to integrate seamlessly into various healthcare environments and aims to provide a more accurate and patient-friendly alternative to existing imaging technologies. These results will be presented in future scientific forums, as the company continues to demonstrate IzoView's capabilities and clinical advantages.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。